Principal Analyst, Datamonitor Healthcare
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Amanda Micklus
Eli Lilly made a big commitment to immuno-oncology with its $1.8 billion deal for CureVac's mRNA vaccines. Amneal and Impax merged, creating the fifth-largest generics company in the US. Billion-dollar aggregates were reached in FOPOs, debt, and late-stage venture pharma financing.
Regenerative medicine has made advances in recent years to emerge as one of the key fields with a chance of addressing, and even curing, diseases that until now had few or no treatment options.
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
Halozyme will use its Enhanze technology to improve the delivery of BMS's immuno-oncology drugs in a new $1.9 billion deal; for $725 million up front and $375 million in earn-outs, Teleflex expanded its urology device portfolio with the NeoTract buy. Device financing surged due to CooperSurgical's $1.1 billion bridge loan, which is helping to support the acquisition of Teva's Paragard IUD.
At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.